

25
YEARS
COMMITTED
TO GHD CARE



We have high expectations because they do too

In a child's mind, all dreams are within reach. We share the same boundless aspirations for our patients. For more than 25 years, we have been supporting the needs of patients and the growth hormone community. And we will continue to raise our expectations to meet patients' needs.

About growth hormone deficiency (GHD)

GHD is a rare disorder that is estimated to affect **1 in 4000 to 1 in 10,000 children**.

**There are
3 different
types of GHD**



Congenital

Present from birth



Acquired


Caused by trauma, infection, radiation therapy, or brain tumors



Idiopathic

Cause cannot be identified

Common signs include:



Below average height



Younger appearance than peers



Fat around the stomach



Thin, delicate hair



Slow tooth development



Poor nail growth



Doctor portrayal.

Common tests for diagnosis include:

- Growth hormone stimulation test
- Bone age x-ray
- Genetic tests
- MRI or CT scans

Treatment options

Although the goal of reaching normal growth milestones is the same for all children with GHD and their families, therapeutic needs and preferences may differ. Currently, a typical treatment plan for GHD includes daily growth hormone injections that some patients may find challenging. Additional options are being explored in hopes of helping appropriate patients better reach their treatment goals.

For more than 25 years, Pfizer has been dedicated to advancing GHD care

At Pfizer, our dedication to the growth hormone community has always been focused on addressing the needs of patients and caregivers. We are committed to delivering quality treatment options that are both efficacious and safe. **For over 25 years**, we have developed different formulations and devices for patients with a variety of growth disorders. Moving forward, we will seek innovative ways to optimize the treatment of growth disorders without compromising the efficacy and safety that patients and caregivers have come to trust.

Since the launch of the first daily growth hormone treatment in the US

we've continued to do research and collect data,

introduced device enhancements, and today,

continue to innovate.

Raising awareness to help overcome gender disparities in diagnosis

Historical trends have shown that boys tend to be diagnosed with GHD twice as often as girls.

The underdiagnosis of girls may reflect the belief in many societies that it is acceptable for girls to be short or "petite."

To ensure that all appropriate patients have an **equal chance** to receive the growth hormone treatment they need, Pfizer is committed to raising awareness about this diagnostic gender disparity.



Addressing the evolving needs of patients and caregivers



“As a parent who has had to give numerous shots over the last 12 years, the easier you make it, the better it is all the way around.”

— Caregiver

Quote heard in market research.

Pfizer understands the impact that GHD can have on the lives of patients and caregivers. We recognize that patients can have individual treatment needs and preferences through different phases in life. That's why we remain devoted to exploring ways to better address the evolving needs of patients and caregivers, and support the health care professionals who treat them every day.



Trusted support and strength in numbers

We know nobody can do it all alone. Pfizer recognizes how valuable it is to be supported with the right information and stay connected to others in the growth hormone community. Below are a few of the many nonprofit patient assistance groups that you may find helpful.



These websites are neither owned nor controlled by Pfizer. Pfizer does not endorse and is not responsible for the content or services of these sites.



For more information on Pfizer's aspirations for patients with growth hormone disorders and other rare diseases, visit www.pfizer.com/science/rare-diseases